Poster Blasts
March 21st 2023
Poster Blasts
March 22nd 2023
Cancer immunotherapies
ID | Title | Author |
|---|---|---|
| 3 | Additional Immunovirotherapy of NUT Carcinoma with the Oncolytic Herpes Simplex Virus T-VEC and the Immune Checkpoint Inhibitor Pembrolizumab | Linus Kloker |
| 4 | A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy | Mary Elisabeth Carter |
| 6 | Acidosis promotes immune escape through the IFN-γ-induced induction of PD-L1 transcription in cancer cells | Dimitri Stowbur |
| 13 | NFAT2 regulates susceptibility of chronic lymphocytic leukemia cells to perforin-mediated killing | Melanie Märklin |
| 15 | CAR T-cell metabolomics reveals dynamic adaptions and distinct metabolic phenotypes upon antigen stimulation | Laimdota Zizmare |
| 17 | timsTOF mass spectrometry-based immunopeptidomics refines tumor antigen identification | Naomi Hoenisch Gravel |
| 22 | DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition | Jens Bauer |
| 24 | Target cell-restricted CD28 bispecific antibodies that sustain antitumor activity of CD3-bispecific antibodies | Latifa Zekri |
| 29 | Preliminary results of a Phase I trial of personalized multi-peptide vaccines combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in CLL patients | Yacine Maringer |
| 30 | Immunopeptidomics of small cell lung cancer | Anna Schöllhorn |
| 34 | Strong immune response to EO2401, a microbiome-derived therapeutic vaccine + nivolumab, in recurrent glioblastoma – The EOGBM1-18/ROSALIE study | Ana Maia dos Santos Leite |
| 37 | Role of prophylactic cranial irradiation in small cell lung cancer and neuroendocrine carcinomas in the era of immune-checkpoint therapy | Jerome-Maurice Dobrowolski |
| 38 | Evaluation of immune checkpoint antigens and stem cell markers on early versus late passage organoids from urothelial carcinoma cells | Simon Walz |
| 43 | Making the effect visible – Nanobodies for in vivo imaging of activated T cells | Desiree I. Frecot |
| 44 | Two birds with one stone: SIRPα nanobodies to visualize and modulate the myeloid cell population | Teresa R. Wagner |
| 44 | Two birds with one stone: SIRPα nanobodies to visualize and modulate the myeloid cell population | Simone Blaeß |
| 57 | Deciphering organ-specific immunoresistance in breast cancer metastasis using multiscale microscopy | Gina Dunkel |
| 62 | Combined T cell and immune checkpoint inhibitor-based immunotherapy induces strong anti-tumoral T cell responses in a mouse model of progressed insular cell carcinomas | Barbara Schörg |
| 63 | Priming Solid Cancers to Heat up and Boost (CAR) T Cell Effector Function | Moustafa Moustafa-Oglou |
| 71 | Analysis of neoantigen distribution, presentation and recognition by patient‑individualized vaccine-induced specific T cells in children with relapsed acute lymphoblastic leukaemia (ALL) | Germano Amorelli |
| 76 | AdCAR-T Tuning to Overcome Immune Escape in Pediatric AML | Anna-Sophia Mast |
| 78 | Role of prophylactic cranial irradiation in small cell lung cancer and neuroendocrine carcinomas in the era of immune-checkpoint therapy | Jerome-Maurice Dobrowolski |
| 81 | Longitudinal PET-monitoring of immunotherapy response by visualization of T cell activation kinetics within the tumor microenvironment | Simone Blaeß |
| 82 | The microbiome as a checkpoint blockade therapy adjuvant | Lukas Mager |
| 92 | Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatment – PerVision | Christian M. Seitz |
| 95 | Modulated signaling in BE-CAR(E) T cells enhances antitumor efficacy | Philip Bucher |
| 107 | Ex vivo generation of cytotoxic CD4 T cells to target solid and hematological cancer | Anna Ohmayer |
| 110 | High frequencies of peripheral Vδ1 T cells are associated with poor overall survival of melanoma patients undergoing PD-1 blockade and a late-differentiated phenotype | Nicola Herold |
| 113 | Sublethal T cell hits induce melanoma cell senescence during immuno-thermal therapy | Oliver Hihn |
| 120 | The triplebody SPM-2 (CD123-16-33) efficiently lyses MOLM-13 and pediatric AML blasts in combination with NK cells | Florian Heubach |
| 125 | Pan-B Cell Targeting by Adapter CAR T Cells (AdCAR-T) Prevents Antigen Escape in B-phenotypic malignancies | Simon Krost |
| 133 | Loss of TP53 in gastric cancer activates a pro-inflammatory program resulting in novel vulnerabilities for immune cell-based therapeutic approaches | Martina Rausch |
| 136 | Small Molecule Inhibitors of p38a improve function and prevent exhaustion of CAR T-cells in Cancer Immunotherapies | Maximilian Feige |
| 139 | Multiplex Targeting by Adapter CAR T Cells (AdCAR-T) to Cope with Inter- and Intratumoral Heterogeneity in Acute Myeloid Leukemia | Daniel Atar |
| 23 | Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies | Latifa Zekri |
| 134 | CRISPR screens in primary CD8+ T-cells identify Kdm2b and Roquin-1 as modulators of T-cell fitness and anti-tumor immunity | Markus Schäfer |
Entry level researcher
ID | Title | Author |
|---|---|---|
| 69 | Mechanistic dissection of the role of Tbx3 and Prdm5 in lineage determination of Primary Liver Cancer | Aram Rahmani Pour |
| 86 | Understanding and targeting immunometabolism to improve therapeutic efficacy of CAR T cells | Nadine Brückner |
| 90 | Combinatorial targeting with (senolytic) CAR therapy | Meike Thiemann |
| 97 | Targeting cancer driver mutations with engineered T cells | Mara Mitstorfer |
| 98 | CAR NK cells in the context of senescent tumor cells | Karlotta Bartels |
| 101 | Reciprocal interaction between senescent tumor cells and CAR T cells | Steffen Hardy |
| 104 | Development and Validation of a Novel Liquid Chromatography-Mass Spectrometry Methodology for GMP-conform Quality Control of Peptide Vaccine Cocktails in Individualized Immunotherapy Setting | Melek Tutku Özbek |
| 124 | Role for Girdin and Daple in melanoma progression and therapy resistance | Ana Villar |
| 137 | Boosting ORFV vector vaccine efficacy by triggering innate immune signaling and optimizing antigen expression of antigen presenting cells | Matthias Helmold |
| 138 | Improving the efficacy of parapoxvirus vector-based tumor vaccines | Verena Haug |
| 142 | Determining the dynamics of immunity to influenza vaccination in cancer patients using multi-omics and repertoire profiling tools | Carlotta Schieler |
| 146 | Distinct genetic ablations increase memory formation in CD19 CAR T cells | Lukas Schönauer |
Functional and molecular multiparametric imaging of cancer
ID | Title | Author |
|---|---|---|
| 9 | Deuterium Metabolic Imaging – Rediscovery of a Powerful Imaging Tool to Study In Vivo Metabolism | Laura Kuebler |
| 10 | Systematic Side-by-Side Comparison of [18F]Olaparib and [18F]Talazoparib as PARP Imaging Agents in an HR-Deficient Breast Cancer Xenograft Model | Sophie Stotz |
| 26 | Establishing Fluorescence Lifetime Imaging Microscopy to determine responsiveness of Patient Derived Microtumors to different cancer therapies | Sally Williamson |
| 27 | Marker-free identification of immune cells in the tumor microenvironment | Julia Alber |
| 41 | MRI for tissue classification of subcutaneus colon cancer using oxygen enhanced, dynamic contrast enhancement (DCE) MRI and [18F]FAZA PET | Marta Vuozzo |
| 45 | Clinical application of [18F]FPyGal: the detection of in vivo senescence | Jonathan Cotton |
| 46 | In vivo evaluation of [18F]Fluoroethyl Fucose: a PET tracer for imaging and studying tumor senescence | Jonathan Cotton |
| 47 | Evaluation of a New Senescence Tracer Generation based on FPyGal | Francisco José Reche Pérez |
| 64 | Image guided multimodal investigations of human breast cancer tissue correlate [18F]-FDG tracer uptake with oxidative stress patterns and decipher distinct metabolic phenotypes in tumor center and periphery depending on hormone receptor and HER2 status | Christoph Trautwein |
| 66 | Label-free imaging for in situ drug efficacy testing on patient-derived cancer organoids | Julia Marzi |
| 72 | Immunological Profiling of Cancer by automated Ultra-High Content Imaging | Sophia Scheuermann |
| 75 | S3-CIMA: Supervised spatial single-cell image analysis for the identification of disease-associated cell type compositions in tissue | Sepideh Babaei |
| 83 | Non-invasive detection of extracellular lactosis and acidosis by shift/acido CEST MRI | Anaïs Choffart |
| 84 | Impact of the metabolic interplay between immune cells and cancer cells during immunotherapy response: a multimodal imaging study | Sixing Li |
| 94 | [89Zr]Zr-DFO-durvalumab PET/CT to predict responses to neo-adjuvant durvalumab in early-stage non-small cell lung cancer | Evelien Van Genugten |
| 119 | [18F]AlF-RESCA-GSA a potential radiotracer for non-invasive staging hepatocellular carcinomas | Kimia Samadikhah |
Functional target discovery, preclinical models and new drugs in oncology
ID | Title | Author |
|---|---|---|
| 8 | Generation and characterization of novel mouse models for OAT2 and OAT7 located in the sinusoidal membrane of hepatocytes | Anne Nies |
| 11 | Understanding and exploiting treatment-induced vulnerabilities in experimental glioma for novel combination therapies: Argyrin F plus PD-1 blockade | Bianca Walter |
| 19 | A preclinical assay system comprised of patient derived microtumors combined with protein profiling and immunophenotyping for assessment of individualized treatment responses | Christian Schmees |
| 20 | Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients | Gyuntae Bae |
| 25 | Characterization of the exome, transcriptome, and immunopeptidome to map alterations in newly diagnosed and recurrent glioblastoma | Marissa L. Dubbelaar |
| 39 | Prior neoadjuvant chemotherapy correlates with reduced culture e6ciency in patient derived bladder cancer organoids | Simon Walz |
| 42 | Functional characterization of therapy response to Somatostatin Receptor Analogs in a novel in vitro model of pancreatic neuroendocrine neoplasms | Katharina Gries |
| 49 | 1st in class small molecule inhibitors of MKK4 to overcome resistance towards KRASG12C or MEK inhibitors in Non-small cell lung cancer | Moritz Schmidt |
| 51 | Development and characterization of kinase sparing TPX2-tethering Aurora Kinase A ligands for the therapy of cancer | Athina Anastasia Moschopoulou |
| 55 | Exploiting LXRalpha activation for lipotoxic cancer therapies | Pascal Wölffing |
| 56 | An optimized system for genome-scale CRISPR screens identifies in vivo dependencies in pancreatic cancer | Vivien Vogt |
| 60 | Development and Evaluation of B7-H3 (CD276) targeted Adapter Molecules for Theranostic Application in the Context of the AdapterCAR (AdCAR) Platform | Beate Kristmann |
| 67 | A novel CRISPR/Cas9 knockout library uncovers pan-essential miRNAs in human cancer cell lines | Daniel J. Merk |
| 68 | Co-transcriptional splicing is a vulnerability of Ras-driven cells | Verena Wagner |
| 70 | In vivo RNAi screen identifies TNMD as a Tumor Suppressor Gene in Liver Cancer | Aram Rahmani Pour |
| 74 | Generation of TCR-transgenic virus-specific T cells by lentiviral transduction as a source for use in research and clinics | Anne-Marie Arendt |
| 77 | SMARCC1 controls oncogenic NOTCH1 signaling in T-cell acute lymphoblastic leukemia | Khalid Shoumariyeh |
| 79 | A Sentinel Lymph Node procedure in early-stage lung cancer: ex-vivo exploration and first clinical results | Desi ter Woerds |
| 80 | The p110 alpha isoform in the PI3K pathway as a promising target for targeted therapy for BRAF mutant malignant melanoma | Heike Niessner |
| 85 | Inflammasome in a cage: NLRP3 forms oligomeric 'cages' to mediate NLRP3 activation | Liudmila Andreeva |
| 89 | Effects of targeted YAP/TAZ-TEAD inhibition on mesothelioma | Hanne Hillen |
| 91 | Discovering novel therapeutic targets for drug-induced senescence in liver cancer | Ana Tapia-Abellan |
| 96 | Development and Characterization of the First-in-Class Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) inhibitor | Ricardo Serafim |
| 102 | Design and synthesis of novel fluorescently labeled analogs of Vemurafenib, targeting MKK4 | Leon Katzengruber |
| 105 | Identifying biomarkers for selinexor response in HCC | Vanessa Hollfoth |
| 106 | Novel AurkA ligands as therapy option for p53-altered carcinoma | Juliander Reiner |
| 108 | Targeting the R-Spine: Design, Synthesis and Biological Evaluation of Novel Type I½ p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency and Prolonged Target Residence Time: A Promising Treatment Option for Colorectal Cancer | Frederik Hacker |
| 109 | Development of a high-throughput system for advanced functional cell analysis for 2D and 3D cell ensembles | Sonja Stoelzle-Feix |
| 111 | Don't you know that you're lipotoxic? Structural determinants of LXR-mediated lipotoxicity | Júlia Galvez Bulhões Pedreira |
| 112 | Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity | Michael Forster |
| 114 | From off-to on-target: New BRAF inhibitor template derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4) | Valentin Wydra |
| 115 | Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors | Masanja Trautz |
| 117 | Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) | Pascal Sander |
| 121 | Running in harmony: HUWE1 coordinates RNAPII-dependent ATM signaling at collisions with replication forks | Elias Einig |
| 127 | Don't you know that you're lipotoxicity? Structural determinants of LXR-mediated lipotoxicity | Júlia Galvez Bulhões Pedreira |
| 129 | Overexpression of Oncogenic Inhibitory-ASPP (apoptosis stimulating protein of p53) Results in Therapy Resistance and Adverse Outcome in AML | Mihada Bajrami Saipi |
| 130 | Harnessing Endogenous ADAR for Therapy | Hakariya Hayase |
| 135 | Short term Antibiotics Treatment increases Liver Tumorigenesis via induction of Long Term Dysbiosis | Svenja Schütte |
| 141 | Sorafenib drives mitophagy across hepatocellular cell boundaries through tunneling nanotubes | Ana Luiza Diogo de Oliveira |
| 147 | Modeling Leukemia Development in context of Congenital Neutropenia | Haaf Jeremy |
Other topics
ID | Title | Author |
|---|---|---|
| 2 | PARP inhibitors effectively reduce melanoma cell growth and synergize with MAPK inhibitors through a synthetic lethal interaction in vitro and in vivo | Lisa Marie Fröhlich |
| 7 | PET Imaging of Senescence in a Pulmonary Fibrosis Mouse Model | Nicolas Bézière |
| 12 | NFAT1 and NFAT2 are major regulators in NK cell immunosurveillance | Melanie Märklin |
| 32 | Phase I/II trial of a peptide-based COVID-19 vaccine to induce SARS‑CoV-2-specific T cell responses in cancer patients with B cell deficiency | Annika Nelde |
| 36 | Genetic-profiling in a real-life cohort of sarcoma patients for identifying potential therapeutic targets | Branko Calukovic |
| 52 | MYC determines lineage commitment in primary liver tumorigenesis | Luana D'Artista |
| 59 | Iron accumulation drives fibrogenesis, senescence, and the senescence-associated secretory phenotype | Mate Maus |
| 61 | Imaging immune cell activation in non-alcoholic steatohepatitis by in vivo PET/MRI using the radiotracer [18F]FAC | Vera Jörke |
| 65 | Explainable diagnosis by leveraging human-interpretable features through mutual information minimization | Erick Cobos |
| 73 | Stratification of ovarian cancer borderline from high-grade serous carcinoma patients via blood serum NMR spectroscopy of metabolites, lipoproteins and inflammatory markers | Georgy Berezhnoy |
| 88 | Diffusion phantom with tissue-like MR properties relevant to the application of DW-MRI in cancer | Victor Fritz |
| 103 | Establishment of an innovate closed vector production platform | Florian Schinle |
| 122 | Experimental Treatment with ATR Inhibitors (ATRi): Challenges in Trial Recruitment | Mihada Bajrami Saipi |
| 131 | Cytomegalovirus-specific antibody titers associate with a late stage differentiated T cell signature and predict poorer survival in melanoma patients under anti-PD-1 blockade | Kilian Wistuba-Hamprecht |
| 132 | The dimeric deubiquitinase Usp28 integrates 53bp1 and Myc functions to limit DNA damage | Chao Jin |
| 143 | 1st in Class Small Molecule Inhibitors of MKK4 for the Treatment of Acute and Chronic Liver Diseases | Stefan Zwirner |
| 148 | Generation of enhanced artificial miRNAs for RNAi-based therapeutics | Giuseppe Militello |